Uncategorized

Apple announces store closures amid major retail problem

Just months after temporarily shuttering all its retail stores in the United Arab Emirates amid escalating geopolitical tensions, Apple is making another significant adjustment to its retail footprint, this time in the U.S. The technology giant has confirmed plans to permanently close three Apple Store locations in three states later this month. While the closures

Apple announces store closures amid major retail problem Read More »

National mall footwear giant closes 82 stores as shoppers trade up

If you think inflation means stores are dropping prices to win consumers back, think again. One of America’s historic footwear giant is actually betting on higher-priced products, and closing stores at your local malls. The way we buy shoes has radically transformed. Stiff dress shoes have been replaced by versatile comfort, according to the US

National mall footwear giant closes 82 stores as shoppers trade up Read More »

New study: Purchasing power is shrinking across the country

Consumers feel the “pinch” of inflation when prices rise faster than income, and Florida residents are the hardest hit. A recent study from the fintech company SensaPay estimated that from 2023 to 2026, Floridians lost the equivalent of $8,222 in income to increasing costs on a range of necessary expenses, including housing, insurance, healthcare, groceries

New study: Purchasing power is shrinking across the country Read More »

Molecule to Medicine: How Daraxonrasib is Rewriting Pancreatic Cancer Drug Development

Monash University’s Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a 500‑patient phase 3 trial for previously treated metastatic pancreatic cancer (RASolute 302; NEJM, May 31, 2026). Developed from an academic spinout and advanced through acquisition and optimization,

Molecule to Medicine: How Daraxonrasib is Rewriting Pancreatic Cancer Drug Development Read More »

Blackstone, Cliffwater cap withdrawals amid credit turmoil

Private credit has long appealed to investors seeking steady returns and the perception of accessible capital. But events over the past week may have challenged those expectations. Blackstone and Cliffwater both restricted investor withdrawals from their flagship private lending funds after second-quarter redemption requests surged past quarterly limits. The restrictions come as the $1.8 trillion

Blackstone, Cliffwater cap withdrawals amid credit turmoil Read More »

Oracle faces vital AI reality check in upcoming earnings

There are times when one company’s results stop being just about that company and become a referendum on an entire sector thesis. For AI cloud infrastructure, that moment arrives on June 10, when Oracle (ORCL) reports fiscal fourth-quarter 2026 results after the market closes. The setup is significant. Oracle’s remaining performance obligations hit $553 billion

Oracle faces vital AI reality check in upcoming earnings Read More »